Which has higher valuation & earnings, SMTI or NYXH?

Sanara MedTech has higher revenue and earnings than Nyxoah. Sanara MedTech is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanara MedTech $107.48M 2.18 -$37.56M -$3.77 N/A Nyxoah $15.33M 3.54 -$101.92M -$2.48 N/A

Is SMTI or NYXH more profitable?

Sanara MedTech has a net margin of -31.23% compared to Nyxoah's net margin of -543.21%. Sanara MedTech's return on equity of -3.19% beat Nyxoah's return on equity. Company Net Margins Return on Equity Return on Assets Sanara MedTech -31.23% -3.19% -0.56% Nyxoah -543.21% -163.73% -80.24%

Which has higher valuation & earnings, OBIO or NYXH?

Orchestra BioMed has higher revenue and earnings than Nyxoah. Orchestra BioMed is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Orchestra BioMed $32.72M 6.84 -$52.70M -$0.97 N/A Nyxoah $15.33M 3.54 -$101.92M -$2.48 N/A

Is OBIO or NYXH more profitable?

Orchestra BioMed has a net margin of -166.96% compared to Nyxoah's net margin of -543.21%. Orchestra BioMed's return on equity of -157.46% beat Nyxoah's return on equity. Company Net Margins Return on Equity Return on Assets Orchestra BioMed -166.96% -157.46% -60.18% Nyxoah -543.21% -163.73% -80.24%

Which has higher earnings & valuation, RXST or NYXH?

RxSight has higher revenue and earnings than Nyxoah. RxSight is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RxSight $127.48M 1.69 -$38.94M -$1.13 N/A Nyxoah $15.33M 3.54 -$101.92M -$2.48 N/A

Is RXST or NYXH more profitable?

RxSight has a net margin of -36.58% compared to Nyxoah's net margin of -543.21%. RxSight's return on equity of -17.01% beat Nyxoah's return on equity. Company Net Margins Return on Equity Return on Assets RxSight -36.58% -17.01% -15.12% Nyxoah -543.21% -163.73% -80.24%

Which has better earnings and valuation, NYXH or FOCL?

FocalTherics has higher revenue and earnings than Nyxoah. FocalTherics is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nyxoah $15.33M 3.54 -$101.92M -$2.48 N/A FocalTherics $74.07M 3.05 -$29.25M -$0.81 N/A

Is NYXH or FOCL more profitable?

FocalTherics has a net margin of -41.47% compared to Nyxoah's net margin of -543.21%. FocalTherics' return on equity of -137.61% beat Nyxoah's return on equity. Company Net Margins Return on Equity Return on Assets Nyxoah -543.21% -163.73% -80.24% FocalTherics -41.47% -137.61% -40.62%

Which has better earnings and valuation, EMBC or NYXH?

Embecta has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Embecta $1.04B 0.19 $95.40M $1.90 1.73 Nyxoah $15.33M 3.54 -$101.92M -$2.48 N/A

Is EMBC or NYXH more profitable?

Embecta has a net margin of 10.73% compared to Nyxoah's net margin of -543.21%. Embecta's return on equity of -23.96% beat Nyxoah's return on equity. Company Net Margins Return on Equity Return on Assets Embecta 10.73% -23.96% 14.12% Nyxoah -543.21% -163.73% -80.24%

Nyxoah (NYXH) Competitors

$1.40 -0.07 (-4.76%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$1.40 +0.01 (+0.36%)

As of 07/24/2026 07:34 PM Eastern

Compare

NYXH vs. SMTI, OBIO, RXST, FOCL, and EMBC

Should you buy Nyxoah stock or one of its competitors? MarketBeat compares Nyxoah with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nyxoah include Sanara MedTech (SMTI), Orchestra BioMed (OBIO), RxSight (RXST), FocalTherics (FOCL), and Embecta (EMBC). These companies are all part of the "medical equipment" industry.

How does Nyxoah compare to Sanara MedTech?

Sanara MedTech (NASDAQ:SMTI) and Nyxoah (NASDAQ:NYXH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

In the previous week, Sanara MedTech and Sanara MedTech both had 1 articles in the media. Sanara MedTech's average media sentiment score of 1.87 equaled Nyxoah'saverage media sentiment score.

Company	Overall Sentiment
Sanara MedTech	Very Positive
Nyxoah	Very Positive

8.1% of Sanara MedTech shares are owned by institutional investors. 42.0% of Sanara MedTech shares are owned by insiders. Comparatively, 17.1% of Nyxoah shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Sanara MedTech has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, Nyxoah has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market.

Sanara MedTech has a net margin of -31.23% compared to Nyxoah's net margin of -543.21%. Sanara MedTech's return on equity of -3.19% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-31.23%	-3.19%	-0.56%
Nyxoah	-543.21%	-163.73%	-80.24%

Sanara MedTech has higher revenue and earnings than Nyxoah. Sanara MedTech is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$107.48M	2.18	-$37.56M	-$3.77	N/A
Nyxoah	$15.33M	3.54	-$101.92M	-$2.48	N/A

Sanara MedTech currently has a consensus price target of $34.00, indicating a potential upside of 33.02%. Nyxoah has a consensus price target of $5.96, indicating a potential upside of 325.89%. Given Nyxoah's higher probable upside, analysts clearly believe Nyxoah is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Sanara MedTech beats Nyxoah on 9 of the 14 factors compared between the two stocks.

How does Nyxoah compare to Orchestra BioMed?

Orchestra BioMed (NASDAQ:OBIO) and Nyxoah (NASDAQ:NYXH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

53.2% of Orchestra BioMed shares are owned by institutional investors. 7.5% of Orchestra BioMed shares are owned by insiders. Comparatively, 17.1% of Nyxoah shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Orchestra BioMed had 3 more articles in the media than Nyxoah. MarketBeat recorded 4 mentions for Orchestra BioMed and 1 mentions for Nyxoah. Nyxoah's average media sentiment score of 1.87 beat Orchestra BioMed's score of 0.80 indicating that Nyxoah is being referred to more favorably in the news media.

Company	Overall Sentiment
Orchestra BioMed	Positive
Nyxoah	Very Positive

Orchestra BioMed has a net margin of -166.96% compared to Nyxoah's net margin of -543.21%. Orchestra BioMed's return on equity of -157.46% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-166.96%	-157.46%	-60.18%
Nyxoah	-543.21%	-163.73%	-80.24%

Orchestra BioMed has higher revenue and earnings than Nyxoah. Orchestra BioMed is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$32.72M	6.84	-$52.70M	-$0.97	N/A
Nyxoah	$15.33M	3.54	-$101.92M	-$2.48	N/A

Orchestra BioMed has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, Nyxoah has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market.

Orchestra BioMed currently has a consensus price target of $13.60, indicating a potential upside of 263.64%. Nyxoah has a consensus price target of $5.96, indicating a potential upside of 325.89%. Given Nyxoah's higher probable upside, analysts clearly believe Nyxoah is more favorable than Orchestra BioMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Orchestra BioMed beats Nyxoah on 11 of the 16 factors compared between the two stocks.

How does Nyxoah compare to RxSight?

RxSight (NASDAQ:RXST) and Nyxoah (NASDAQ:NYXH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

RxSight has higher revenue and earnings than Nyxoah. RxSight is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$127.48M	1.69	-$38.94M	-$1.13	N/A
Nyxoah	$15.33M	3.54	-$101.92M	-$2.48	N/A

RxSight has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Nyxoah has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market.

78.8% of RxSight shares are held by institutional investors. 10.1% of RxSight shares are held by company insiders. Comparatively, 17.1% of Nyxoah shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

RxSight currently has a consensus price target of $8.89, suggesting a potential upside of 71.27%. Nyxoah has a consensus price target of $5.96, suggesting a potential upside of 325.89%. Given Nyxoah's stronger consensus rating and higher possible upside, analysts plainly believe Nyxoah is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, RxSight had 3 more articles in the media than Nyxoah. MarketBeat recorded 4 mentions for RxSight and 1 mentions for Nyxoah. Nyxoah's average media sentiment score of 1.87 beat RxSight's score of 1.23 indicating that Nyxoah is being referred to more favorably in the news media.

Company	Overall Sentiment
RxSight	Positive
Nyxoah	Very Positive

RxSight has a net margin of -36.58% compared to Nyxoah's net margin of -543.21%. RxSight's return on equity of -17.01% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.58%	-17.01%	-15.12%
Nyxoah	-543.21%	-163.73%	-80.24%

Summary

RxSight beats Nyxoah on 8 of the 15 factors compared between the two stocks.

How does Nyxoah compare to FocalTherics?

Nyxoah (NASDAQ:NYXH) and FocalTherics (NASDAQ:FOCL) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

62.7% of FocalTherics shares are held by institutional investors. 17.1% of Nyxoah shares are held by company insiders. Comparatively, 10.1% of FocalTherics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Nyxoah has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market. Comparatively, FocalTherics has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market.

In the previous week, FocalTherics had 1 more articles in the media than Nyxoah. MarketBeat recorded 2 mentions for FocalTherics and 1 mentions for Nyxoah. Nyxoah's average media sentiment score of 1.87 beat FocalTherics' score of 1.12 indicating that Nyxoah is being referred to more favorably in the media.

Company	Overall Sentiment
Nyxoah	Very Positive
FocalTherics	Positive

FocalTherics has a net margin of -41.47% compared to Nyxoah's net margin of -543.21%. FocalTherics' return on equity of -137.61% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nyxoah	-543.21%	-163.73%	-80.24%
FocalTherics	-41.47%	-137.61%	-40.62%

Nyxoah presently has a consensus price target of $5.96, suggesting a potential upside of 325.89%. FocalTherics has a consensus price target of $9.00, suggesting a potential upside of 49.25%. Given Nyxoah's higher possible upside, equities research analysts plainly believe Nyxoah is more favorable than FocalTherics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
FocalTherics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

FocalTherics has higher revenue and earnings than Nyxoah. FocalTherics is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$15.33M	3.54	-$101.92M	-$2.48	N/A
FocalTherics	$74.07M	3.05	-$29.25M	-$0.81	N/A

Summary

FocalTherics beats Nyxoah on 10 of the 17 factors compared between the two stocks.

How does Nyxoah compare to Embecta?

Embecta (NASDAQ:EMBC) and Nyxoah (NASDAQ:NYXH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

Embecta has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.04B	0.19	$95.40M	$1.90	1.73
Nyxoah	$15.33M	3.54	-$101.92M	-$2.48	N/A

Embecta has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Nyxoah has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market.

Embecta currently has a consensus price target of $11.00, suggesting a potential upside of 234.35%. Nyxoah has a consensus price target of $5.96, suggesting a potential upside of 325.89%. Given Nyxoah's stronger consensus rating and higher possible upside, analysts plainly believe Nyxoah is more favorable than Embecta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Embecta had 33 more articles in the media than Nyxoah. MarketBeat recorded 34 mentions for Embecta and 1 mentions for Nyxoah. Nyxoah's average media sentiment score of 1.87 beat Embecta's score of 0.10 indicating that Nyxoah is being referred to more favorably in the news media.

Company	Overall Sentiment
Embecta	Neutral
Nyxoah	Very Positive

Embecta has a net margin of 10.73% compared to Nyxoah's net margin of -543.21%. Embecta's return on equity of -23.96% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	10.73%	-23.96%	14.12%
Nyxoah	-543.21%	-163.73%	-80.24%

93.8% of Embecta shares are owned by institutional investors. 1.3% of Embecta shares are owned by insiders. Comparatively, 17.1% of Nyxoah shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Embecta beats Nyxoah on 9 of the 16 factors compared between the two stocks.

Get Nyxoah News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NYXH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NYXH vs. The Competition

Export

Metric	Nyxoah	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$54.27M	$1.68B	$6.87B	$12.26B
Dividend Yield	N/A	N/A	2.67%	9.79%
P/E Ratio	-0.56	74.42	27.14	23.64
Price / Sales	3.54	62.75	517.06	88.99
Price / Cash	N/A	26.11	50.54	59.64
Price / Book	0.98	4.98	10.28	6.07
Net Income	-$101.92M	-$54.76M	$3.60B	$331.99M
7 Day Performance	-10.83%	-6.95%	-1.27%	-0.63%
1 Month Performance	-14.11%	-2.60%	-0.37%	-2.00%
1 Year Performance	-81.53%	-11.12%	18.30%	13.62%

Nyxoah Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NYXH Nyxoah	3.3024 of 5 stars	$1.40 -4.8%	$5.96 +325.9%	-82.0%	$54.27M	$15.33M	N/A	110	Positive News
SMTI Sanara MedTech	2.1257 of 5 stars	$25.50 +2.0%	$34.00 +33.3%	-0.4%	$233.58M	$103.12M	N/A	60
OBIO Orchestra BioMed	4.145 of 5 stars	$3.69 -0.5%	$13.60 +268.6%	+16.1%	$220.96M	$33.48M	N/A	4
RXST RxSight	3.8246 of 5 stars	$5.25 -6.4%	$8.89 +69.3%	-34.6%	$217.35M	$134.48M	N/A	220	Positive News
FOCL FocalTherics	3.4147 of 5 stars	$5.68 +1.2%	$9.00 +58.5%	N/A	$212.89M	$70.53M	N/A	230	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NYXH) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nyxoah (NYXH) Competitors

NYXH vs. SMTI, OBIO, RXST, FOCL, and EMBC

How does Nyxoah compare to Sanara MedTech?

Summary

How does Nyxoah compare to Orchestra BioMed?

Summary

How does Nyxoah compare to RxSight?

Summary

How does Nyxoah compare to FocalTherics?

Summary

How does Nyxoah compare to Embecta?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NYXH vs. The Competition

Nyxoah Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nyxoah (NYXH) Competitors

NYXH vs. SMTI, OBIO, RXST, FOCL, and EMBC

How does Nyxoah compare to Sanara MedTech?

Does the media favor SMTI or NYXH?

Do insiders & institutionals believe in SMTI or NYXH?

Which has more risk & volatility, SMTI or NYXH?

Is SMTI or NYXH more profitable?

Which has higher valuation & earnings, SMTI or NYXH?

Do analysts recommend SMTI or NYXH?

Summary

How does Nyxoah compare to Orchestra BioMed?

Do insiders & institutionals believe in OBIO or NYXH?

Does the media favor OBIO or NYXH?

Is OBIO or NYXH more profitable?

Which has higher valuation & earnings, OBIO or NYXH?

Which has more risk & volatility, OBIO or NYXH?

Do analysts recommend OBIO or NYXH?

Summary

How does Nyxoah compare to RxSight?

Which has higher earnings & valuation, RXST or NYXH?

Which has more risk and volatility, RXST or NYXH?

Do institutionals & insiders have more ownership in RXST or NYXH?

Do analysts prefer RXST or NYXH?

Does the media refer more to RXST or NYXH?

Is RXST or NYXH more profitable?

Summary

How does Nyxoah compare to FocalTherics?

Do institutionals & insiders have more ownership in NYXH or FOCL?

Which has more risk & volatility, NYXH or FOCL?

Does the media refer more to NYXH or FOCL?

Is NYXH or FOCL more profitable?

Do analysts rate NYXH or FOCL?

Which has better earnings and valuation, NYXH or FOCL?

Summary

How does Nyxoah compare to Embecta?

Which has better earnings and valuation, EMBC or NYXH?

Which has more volatility & risk, EMBC or NYXH?

Do analysts prefer EMBC or NYXH?

Does the media prefer EMBC or NYXH?

Is EMBC or NYXH more profitable?

Do insiders and institutionals have more ownership in EMBC or NYXH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NYXH vs. The Competition

Nyxoah Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools